CV Therapeutics News

Rule Breaker investing is all about finding innovative growth stocks, like medical-robotics manufacturer Intuitive Surgical or Internet search-ad giant Google .

The money from CV Therapeutics ' recently approved medical diagnostic compound Lexiscan keeps rolling in.

Biopharmaceutical company CV Therapeutics Inc. said Tuesday it has received a milestone payment of $10 million from TPG-Axon Capital related to the commercial launch of its stress agent Lexiscan.

On Friday, the duo announced that the FDA delayed the review of their blood-disorder drug Promacta by as much as three months.

In addition, Zacks Equity Research provides analysis on CAI International , CV Therapeutics and National Semiconductor .

CV Therapeutics Inc. has enjoyed quite a turn of fortune almost a year after doubts about its angina drug Ranexa had the company considering "strategic alternatives." Federal approval of Lexiscan, which ...

Oncothyreon said it had appointed Daniel Spiegelman, the CFO at CV Therapeutics in Palo Alto, Calif., and Stephen Burley, the chief scientific officer of SGX Pharmaceuticals in San Diego, Calif., to its board.

From: Biniam Haile \ Date: Wed May 28 2008 - 12:17:01 EDT 5 Stocks Approaching Greatness By Rich Duprey May 28, 2008 Some companies are obviously great investments -- in hindsight.

Oncothyreon Inc. today announced that Daniel K. Spiegelman and Stephen K. Burley, M.D., D.Phil. have joined its board of directors for three-year terms.

In the pharma days of yore , drug approvals were bountiful -- and for some companies, they still are. via The Motley Fool

Louis Lange - Chairman and CEO Dan Spiegelman - CFO Analysts Bret Holley - Oppenheimer & Co Thomas Wei - Piper Jaffrey Michael Castor - SIO Capital Jim Birchenough - Lehman Brothers Alan Carr - Needham Steve ... via Seeking Alpha

“This positive opinion from the CHMP brings ranolazine significantly closer to physicians and patients in Europe for the treatment of chronic angina”

Following this positive recommendation from the CHMP, CV Therapeutics expects the European Commission to issue full marketing authorization for ranolazine by the end of June. via Earth Times

It's usually scientists who cause drug companies' stocks to move, but yesterday, it was the money managers' turn. via Motley Fool

The markets were able to shake everything off today after techs and financials delivered more hope than economics could deliver in fear. via Blogging Stocks

And I'm sure CV Therapeutics and Cardiome were jealous . The FDA headache that has been plaguing Pozen and marketing partner GlaxoSmithKline for so long seems to finally be cured. via Fool.com

Shares of CV Therapeutics, Inc . are leaping in pre-market trading after the biopharmaceutical company said after Tuesday's close that TPG-Axon Capital has agreed to pay up to $185 million in exchange for ... via All Stories

CV Therapeutics, Inc. , Geron Corp. and ANADIGICS, Inc. are among the most actively traded companies in Friday's pre-market trading among those with market capitalizations under $750 million. via All Stories

“Lexiscan represents the second novel chemical entity in cardiovascular medicine that CV Therapeutics has received approval for in just over two years”

CV Therapeutics and Astellas Pharma announced that FDA has approved Lexiscan injection, an A2A adenosine receptor agonist, for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging -- ... via EMaxHealth

CV Therapeutics Inc. and Astellas Pharma US Inc. said the Food and Drug Administration approved an injection for coronary artery disease testing, triggering a $12 million milestone payment to CV Therapeutics. via San Jose Business Journal

“This new subgroup analysis shows consistent safety and efficacy across a broader group of angina patients than those studied previously and reaffirms ranolazine as an option for treating chronic angina.”

CHICAGO, April 01, 2008, 2008 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. today announced new data presented at the 57th Annual Scientific Sessions of the of Cardiology shows that Ranexa significantly ... via Med Ad News